Breakthrough T1D CMO Award Signals Focus on Therapy Adoption
Event summary
- Dr. Thomas Danne, CMO of Breakthrough T1D, is receiving the Children with Diabetes President's Award for Innovation.
- The award will be presented on March 13, 2026, at the Advanced Technologies & Treatment for Diabetes conference in Barcelona.
- Dr. Danne previously held leadership positions at Hannover Medical School and the SWEET Registry.
- Breakthrough T1D (formerly JDRF) focuses on T1D research, advocacy, and improving access to therapies.
- Type 1 Diabetes impacts 9.5 million people globally, with nearly 50% of diagnoses occurring in adulthood.
The big picture
The recognition of Dr. Danne highlights Breakthrough T1D's strategic pivot towards not only research but also the practical implementation and adoption of new therapies. This focus on access and adoption is critical given the high cost of T1D treatment and the ongoing need for improved patient outcomes. The award underscores the importance of clinical leadership in driving the organization's mission and navigating the complex landscape of diabetes care.
What we're watching
- Adoption Rate
- How Breakthrough T1D will leverage Dr. Danne's expertise to accelerate the adoption of new therapies among patients and clinicians remains to be seen, given the challenges of reimbursement and patient education.
- SWEET Registry
- The legacy of Dr. Danne's 16-year leadership of the SWEET Registry and its impact on data collection and quality of care will be a key indicator of his influence within the organization.
- Global Reach
- Whether Breakthrough T1D will expand its global initiatives, particularly in regions where access to advanced diabetes care is limited, given Dr. Danne's international experience, warrants observation.
Related topics